Advisory Committee to the Director (ACD), Centers for Disease Control and Prevention (CDC), 62844 [2010-25703]
Download as PDF
<![CDATA[
62844
Federal Register / Vol. 75, No. 197 / Wednesday, October 13, 2010 / Notices
record of the ACBSCT meeting. Meeting
summary notes will be made available on the
HRSA’s Program Web site at https://
bloodcell.transplant.hrsa.gov/ABOUT/
Advisory_Council/.
Those planning to attend are requested to
register in advance. The draft meeting agenda
and a registration form are available on the
HRSA’s Program Web site at https://
bloodcell.transplant.hrsa.gov/ABOUT/
Advisory_Council/.
Registration also can be completed
electronically at https://www.acbsct.com or
submitted by facsimile to Lux Consulting
Group, Inc., the logistical support contractor
for the meeting, at fax number (301) 585–
7741 Attn: Tristan Alexander. Individuals
without access to the Internet who wish to
register may call Tristan Alexander at (301)
585–1261.
FOR FURTHER INFORMATION CONTACT:
Agenda items are subject to change as
priorities dictate.
Contact Person for More Information:
Carmen Villar, M.S.W., Designated Federal
Officer, ACD, CDC, 1600 Clifton Road, NE.,
M/S D–14, Atlanta, Georgia 30333.
Telephone 404/639–7000. E-mail:
GHickman@cdc.gov. The deadline for
notification of attendance is October 25,
2010.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Dated: October 5, 2010.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
Patricia Stroup, Executive Secretary,
Healthcare Systems Bureau, Health
Resources and Services Administration,
5600 Fishers Lane, Room 12C–06,
Rockville, Maryland 20857; telephone
(301) 443–1127.
[FR Doc. 2010–25703 Filed 10–12–10; 8:45 am]
Dated: October 6, 2010.
Wendy Ponton,
Director, Office of Management.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2010–25646 Filed 10–12–10; 8:45 am]
Food and Drug Administration
BILLING CODE 4165–15–P
[Docket No. FDA–2010–N–0001]
Innovations in Technology for the
Treatment of Diabetes: Clinical
Development of the Artificial Pancreas
(an Autonomous System); Public
Workshop
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Advisory Committee to the Director
(ACD), Centers for Disease Control and
Prevention (CDC)
mstockstill on DSKH9S0YB1PROD with NOTICES
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the CDC announces
the following meeting of the
aforementioned committee:
Time and Date: 8:30 a.m.–3 p.m., October
28, 2010.
Place: CDC, 1600 Clifton Road, NE.,
Building 21, Rooms 1204 A/B, Atlanta,
Georgia 30333.
Status: Open to the public, limited only by
the space available. The meeting room
accommodates approximately 50 people. The
public is welcome to participate during the
public comment period. The public comment
period is tentatively scheduled for 2:30 to
2:45 p.m.
Purpose: The committee will provide
advice to the CDC Director on strategic and
other broad issues facing CDC.
Matters to be Discussed: The ACD, CDC
will receive updates from the Global
Workgroup; State, Tribal, Local and
Territorial Workgroup; Surveillance and
Epidemiology Workgroup; and the Policy
Workgroup. The Ethics Subcommittee and
National Biosurveillance Advisory
Subcommittee will provide updates on their
current activities.
VerDate Mar<15>2010
17:22 Oct 12, 2010
Jkt 223001
BILLING CODE 4163–18–P
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of public workshop.
The Food and Drug Administration
(FDA) and the National Institutes of
Health (NIH) are announcing a public
workshop entitled ‘‘Innovations in
Technology for the Treatment of
Diabetes: Clinical Development of the
Artificial Pancreas (an Autonomous
System).’’ The topics to be discussed are
the current state of device systems for
autonomous systems for the treatment of
diabetes mellitus, the challenges in
developing this expert system using
existing technology, a discussion of the
clinical expectations and success
criteria for these systems, and a
discussion of development plans for the
transition of this device system toward
an outpatient setting.
Date and Time: The public workshop
will be held on November 10, 2010,
from 8 a.m. to 5 p.m. Persons interested
in attending this meeting must register
by 5 p.m. on November 3, 2010.
Location: The meeting will be held at
the Hilton Washington, DC North/
Gaithersburg Hotel, 620 Perry Pkwy.,
Gaithersburg, MD 20877.
PO 00000
Frm 00090
Fmt 4703
Sfmt 4703
Contact: Charles Zimliki, Food and
Drug Administration, Center for Devices
and Radiological Health (CDRH), 10903
New Hampshire Ave., Bldg. 66, rm.
2556, Silver Spring, MD 20993–0002,
301–796–6297, Fax: 301–847–8109, email: Charles.Zimliki@fda.hhs.gov.
Registration: Registration is free and
will be on a first-come, first-served
basis. To register for the public
workshop, webinar or onsite attendance,
please visit the following Web site:
https://www.fda.gov/MedicalDevices/
NewsEvents/WorkshopsConferences/
ucm226251.htm (select the appropriate
meeting from the list). Please provide
complete contact information for each
attendee, including name, title,
affiliation, address, e-mail, and
telephone number. For those without
Internet access, please call Victoria
Wagman at 301–796–6581 to register.
Registration requests should be received
by 5 p.m. on November 3, 2010. Early
registration is recommended because
seating is limited and therefore FDA/
NIH may limit the number of
participants from each organization. If
time and space permits, onsite
registration on the day of the public
meeting will be provided beginning at 7
a.m.
If you need special accommodations
due to a disability, please contact Susan
Monahan (e-mail:
Susan.Monahan@fda.hhs.gov) at least 7
days in advance.
SUPPLEMENTARY INFORMATION:
I. Background
CDRH has undertaken an initiative to
proactively facilitate medical device
innovation to address unmet public
health needs. As part of this initiative,
CDRH with NIH have focused on the
development of the artificial pancreas
(or Autonomous System) for the
treatment of diabetes mellitus. An
artificial pancreas is a medical device
that links a glucose monitor to an
insulin infusion pump where the pump
automatically takes action (using a
control algorithm) based upon the
glucose monitor reading. As control
algorithms can vary significantly, there
are a variety of artificial pancreas
systems currently under development.
These systems can range from low
glucose suspend, to control-to-range, to
control-to-target, to bihormonal control
where each device has different
purposes or intended uses for
controlling blood sugars. In addition,
most research in this area uses existing
medical device technology, which might
limit the performance and evaluation of
these systems. Given these device
limitations, preliminary research has
focused on evaluating these systems in
E:\FR\FM\13OCN1.SGM
13OCN1
]]>Agencies
[Federal Register Volume 75, Number 197 (Wednesday, October 13, 2010)]
[Notices]
[Page 62844]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-25703]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Advisory Committee to the Director (ACD), Centers for Disease
Control and Prevention (CDC)
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the CDC announces the following meeting
of the aforementioned committee:
Time and Date: 8:30 a.m.-3 p.m., October 28, 2010.
Place: CDC, 1600 Clifton Road, NE., Building 21, Rooms 1204 A/B,
Atlanta, Georgia 30333.
Status: Open to the public, limited only by the space available.
The meeting room accommodates approximately 50 people. The public is
welcome to participate during the public comment period. The public
comment period is tentatively scheduled for 2:30 to 2:45 p.m.
Purpose: The committee will provide advice to the CDC Director
on strategic and other broad issues facing CDC.
Matters to be Discussed: The ACD, CDC will receive updates from
the Global Workgroup; State, Tribal, Local and Territorial
Workgroup; Surveillance and Epidemiology Workgroup; and the Policy
Workgroup. The Ethics Subcommittee and National Biosurveillance
Advisory Subcommittee will provide updates on their current
activities.
Agenda items are subject to change as priorities dictate.
Contact Person for More Information: Carmen Villar, M.S.W.,
Designated Federal Officer, ACD, CDC, 1600 Clifton Road, NE., M/S D-
14, Atlanta, Georgia 30333. Telephone 404/639-7000. E-mail:
GHickman@cdc.gov. The deadline for notification of attendance is
October 25, 2010.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining
to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention
and the Agency for Toxic Substances and Disease Registry.
Dated: October 5, 2010.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2010-25703 Filed 10-12-10; 8:45 am]
BILLING CODE 4163-18-P
